The non-alcoholic fatty liver disease market is estimated to be worth $35 billion.

However, the side effects associated with the current treatments in development could limit the growth of the global fatty liver treatment market.

Immuron Limited, (ASX: IMC) which is working in the realm of oral immunotherapies, is looking to buck this trend with the only asset in development globally that could address high unmet medical needs for infectious diseases in multiple blockbuster markets.

As IMC prepares to list on the NASDAQ, it is set to hit key milestones for its immunotherapy treatments as it also looks to attract the attention of a big pharma partner.

The news has been free flowing for IMC lately and more is expected to come.

Not only has IMC expanded its major collaboration with the US Department of Defence to develop an anti-infective human therapeutic, it has also completed manufacturing supplies of IMM-529 for its C. difficile Phase I/II Clinical Trials set to commence in the next few weeks.

IMC has also now completed recruitment for its Phase II Clinical Trials for IMM-124E, its cornerstone treatment for a range of fatty liver diseases.

The information on this page should not be the only trigger for your investment decision. Click on the link below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.

It’s been non-stop for IMC, with the company recently announcing the completion of the first stage of its colitis preclinical program for IMM-124E at the University of Zürich in Switzerland.

This piece of news alone garnered a great deal of attention for the company and with continued newsflow expected, a NASDAQ listing imminent and more milestones to come by the end of the year, its onwards and upwards for this proactive biotech.